Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04722575
Recruitment Status : Recruiting
First Posted : January 25, 2021
Last Update Posted : April 13, 2022
Sponsor:
Collaborator:
Clinical Research Technology S.r.l.
Information provided by (Responsible Party):
Fondazione Melanoma Onlus

Brief Summary:
Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).

Condition or disease Intervention/treatment Phase
Melanoma Drug: Cobimetinib 20 MG Oral Tablet Drug: Vemurafenib 240 Mg Oral Capsule Drug: Atezolizumab 1200 MG in 20 ML Injection Phase 2

Detailed Description:

Melanoma represents a considerable health burden and an ongoing area of unmet need in oncology. Despite melanoma accounts for only 1% of diagnosed skin cancers, it is the cause of most skin cancer-related deaths. Until recently, limited effective treatment options were available to patients with advanced melanoma. Historically, response rates to conventional chemotherapy and immunomodulation therapy (interleukin-2 or interferon-γ) have been reported at approximately 5-19%.

Adjuvant immune checkpoint blockade (ICB) and target therapy improve outcomes of patients with high-risk resectable melanoma. It has recently been demonstrated that treatment with neoadjuvant and adjuvant targeted therapy (dabrafenib and trametinib) is associated with a high pathologic complete response (pCR) rate and improved outcomes over surgery alone. However, treatment with ICB has not been well studied in the neoadjuvant setting, despite preclinical studies suggesting that neoadjuvant administration of ICB is associated with improved survival and enhanced anti-tumour immune responses compared to the same therapy administered in the adjuvant setting.

The advantage of neoadjuvant trials is the availability of blood and tumour tissue samples before and after systemic therapy for the conduct of novel mechanistic and biomarker studies in the circulation and the tumour microenvironment.

Prospective neoadjuvant clinical trials with targeted (dabrafenib/trametinib combo) or immunotherapeutic agents (nivolumab alone or nivolumab/ipilimumab combo) and combinations are now running in a subgroup of highrisk melanoma patients with pooled overall promising preliminary results of high rates of pathologic complete responses (pCRs, 30-50%) and early data of positive correlation between pCR and relapse-free survival. Based on the available results to date, we aim to conduct a randomized, noncomparative phase II trial to define the role of neoadjuvant plus adjuvant target and immunotherapy, given in combination or sequence, in patients with high risk surgically resectable melanoma.This approach has the potential to define whether neoadjuvant treatment has antitumour activity and whether it reduces the risk of relapse after surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The study will be conducted according to an open-label, randomized, not comparative phase II design. Three arms for a total of 88 patients will be considered.

BRAF mutated patients will be randomized in two arms: Arm A and Arm B (27 patients per arm). BRAF WT patients will be included in Arm C (34 patients).

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: "NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"
Actual Study Start Date : October 12, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : June 2027

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: ARM A

Arm A BRAF mutated patients. Over a period of 6 weeks (1) + (2):

  1. Vemurafenib 960 mg bid p.o. from week 1 to week 6.
  2. Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.

After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks

Drug: Cobimetinib 20 MG Oral Tablet
Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
Other Name: Cotellic

Drug: Vemurafenib 240 Mg Oral Capsule
960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
Other Name: Zelboraf

Drug: Atezolizumab 1200 MG in 20 ML Injection
840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
Other Name: Tecentriq

Experimental: ARM B

Arm B BRAF mutated patients. Over a period of 6 weeks (1) + (2) + (3):

  1. Vemurafenib 720 mg bid p.o. from week 1 to week 6.
  2. Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6. Week 4 off.
  3. Atezolizumab 840 mg IV for 2 cycles (day 1 of week 4 and day 1 of week 7).

After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks

Drug: Cobimetinib 20 MG Oral Tablet
Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
Other Name: Cotellic

Drug: Vemurafenib 240 Mg Oral Capsule
960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
Other Name: Zelboraf

Drug: Atezolizumab 1200 MG in 20 ML Injection
840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
Other Name: Tecentriq

Experimental: ARM C

Arm C BRAF WT patients. Over a period of six weeks (1) + (2):

  1. Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6,
  2. Atezolizumab 840 mg IV for 2 cycles (day 1 of week 1 and day 1 of week 4).

After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks

Drug: Cobimetinib 20 MG Oral Tablet
Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
Other Name: Cotellic

Drug: Atezolizumab 1200 MG in 20 ML Injection
840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
Other Name: Tecentriq




Primary Outcome Measures :
  1. Pathologic Complete Response (pCR) rate (Centrally/Independently determined) [ Time Frame: At surgery (from week 8 to week 9) ]
    Defined as the lack of all signs of cancer in tissue samples removed during surgery


Secondary Outcome Measures :
  1. Recurrence-free survival (RFS) [ Time Frame: At 2-years, 3-years and at the end of the study ]
    Defined as the time from randomisation to recurrence event or last follow-up

  2. Overall survival (OS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years ]
    Defined as the time from the date of randomisation to the date of death due to any cause

  3. pORR [ Time Frame: At surgery (from week 8 to week 9) after neoadjuvant treatment and at disease relapse up to 5 years ]
    Defined as the sum of pathologic complete responses (pCRs), near pathologic complete responses near pCRs) and pathologic partial responses (pPRs).

  4. Safety - adverse events [ Time Frame: Continuosly during the trial while on treatment or within 30 days after the last study treatment ]
    All AEs, Grade 3 to 4 AEs, serious adverse events (SAEs), deaths, AEs of special interest (AESIs), and AEs leading to treatment discontinuation or withdrawal from the study

  5. Molecular and immunophenotypic changes [ Time Frame: At baseline, prior to surgery, every 12 weeks during adjuvant treatment and at the disease relapse up to 5 years ]
    Immunoscore, Circulating cytokines and chemokines profiling, Metabolomic profiling,Tumour mutational burden, Myeloid-derived suppressors cells, immune cell subtypes expression and lymphocyte activation, Additional analysis of protein levels (i.e. CCR5), DNA mutations, and/or mRNA analysis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients of either sex aged ≥18 years;
  2. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form;
  3. Patients must have histologically or cytologically confirmed Stage IIIB/C/D or oligometastatic stage IV1 resectable melanoma. The definition of resectability can be determined by the patient's surgical oncologist and verified via discussion at Multidisciplinary Tumour Conference attended by melanoma medical and surgical oncology staff. Resectable tumours are defined as having no significant vascular, neural or bony involvement. Only cases where a complete surgical resection with tumour-free margins can safely be achieved are defined as resectable;
  4. All patients must have a BRAF V600E/K mutation status known;
  5. Patients must be medically fit enough to undergo surgery as determined by the surgical oncology team;
  6. Patients must have measurable disease, defined by RECIST 1.1;
  7. ECOG performance status 0-1; *
  8. Patients must have organ and marrow function
  9. Absence of any psychological, familiar or social condition that may affect compliance with study protocol and schedule follow-up;
  10. Female subjects of childbearing potential must have a negative pregnancy test result at baseline and must practice a reliable method of contraception for the total study duration plus 23 weeks (i.e. 30 days plus the time required for experimental drugs to undergo five half-lives) after the last dose of experimental drugs; *
  11. Men who are sexually active with women of childbearing potential must practice a reliable method of contraception for the total study duration plus 31 weeks (i.e. 80 days plus the time required for experimental drugs to undergo five half-lives) after the last dose of experimental drugs.

Exclusion Criteria:

  1. Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug; *
  2. Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, thyroid cancer (except anaplastic) or any cancer from which the patient has been disease-free for 2 years;
  3. Any major surgery within the last 3 weeks;
  4. Pregnancy and/or breast feeding or of childbearing potential and not practicing a reliable method of birth control;*
  5. Unwillingness or inability to follow the procedures required in the protocol; *
  6. Uncontrolled diabetes, hypertension or other medical conditions that may interfere with assessment of toxicity;*
  7. Current use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levels*
  8. Patients with a history of uncontrolled cardiovascular or interstitial lung disease and evidence or risk of retinal vein occlusion or central serous retinopathy;
  9. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment; *
  10. Prior BRAF or MEK directed therapy; patients who have received prior interferon are eligible;
  11. History of retinopathy or any finding at ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy, retinal vein occlusion (RVO), or neovascular macular de generation;
  12. Presence of any of the following risk factors for RVO: a) Uncontrolled glaucoma with intraocular pressures ≥ 21mmHg; b) Serum cholesterol ≥Grade 2; c) Hypertriglyceridemia ≥ Grade 2; d) Hyperglycaemia (fasting) ≥Grade 2;
  13. Correct QT interval > 450msec to baseline, history of congenital long QT syndrome;
  14. Uncontrolled medical condition among which endocrine disorders (such as hypothyroidism, hyperthyroidism and diabetes mellitus);
  15. Other severe medical or psychiatric conditions (like depression) or abnormalities of laboratory tests that may increase the risk associated with study participation or the assumption of Vemurafenib, Atezolizumab and Cobimetinib or that may interfere with the interpretation of study results, which in the judgment of the Investigator can make the patient not eligible for the study;
  16. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, cerebrovascular accident or transient ischemic attack, pulmonary embolism, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent;
  17. History of active primary immunodeficiency;
  18. Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMP and up to 30 days after the last dose of IMP; *
  19. Prior treatment with an anti- PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody;
  20. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients;
  21. Positive test for HBV sAg or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection;
  22. Known history of testing positive for HIV or known AIDS;
  23. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04722575


Contacts
Layout table for location contacts
Contact: Marcello Curvietto +39 (0)81 5903841 curvietto.ma@gmail.com
Contact: Paola Schiavo +39 (0)89 301545 neotim@cr-technology.com

Locations
Layout table for location information
Italy
Ospedale S.M. Annunziata - Azienda USL Toscana Centro Not yet recruiting
Bagno A Ripoli, Firenze, Italy, 50012
Contact: Lorenzo Borgognoni         
IRCCS - Istituto Scientifico Romagnolo per la Cura e lo Studio dei Tumori (I.R.S.T) S.r.l. Not yet recruiting
Meldola, Forlì-Cesena, Italy, 47014
Contact: Massimo Guidoboni, MD         
Principal Investigator: Massimo Guidoboni, MD         
IRCCS San Martino - IST Recruiting
Genova, Italy, 16132
Contact: Francesco Spagnolo         
Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori Not yet recruiting
Milano, Italy, 20133
Contact: Michele Del Vecchio, MD         
Principal Investigator: Michele Del Vecchio, MD         
Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale" Recruiting
Naples, Italy, 80131
Contact: Paolo Ascierto, MD         
Principal Investigator: Paolo Ascierto, Md         
Istituto Oncologico Veneto Recruiting
Padova, Italy, 35128
Contact: Vanna Chiarion Sileni, MD         
Principal Investigator: Vanna Chiarion-sileni, MD         
Sponsors and Collaborators
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.
Investigators
Layout table for investigator information
Study Chair: Paolo Ascierto Fondazione Melanoma Onlus
Layout table for additonal information
Responsible Party: Fondazione Melanoma Onlus
ClinicalTrials.gov Identifier: NCT04722575    
Other Study ID Numbers: NEO-TIM
First Posted: January 25, 2021    Key Record Dates
Last Update Posted: April 13, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fondazione Melanoma Onlus:
resectable melanoma
BRAF mutated
high risk melanoma
wild type
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Atezolizumab
Vemurafenib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action